The serious adverse event reported in the early-stage study resolved quickly, but Chinook Therapeutics said it is suspected to be related to its experimental primary hyperoxaluria therapy. Meanwhile, Human Immunology Biosciences is looking ahead to Phase 3 after its rare kidney disease drug posted positive mid-stage data.
Human Immunology Biosciences aims to stand apart in autoimmune disease drug research with therapies that address cells at the root of a range of allergic and inflammatory disorders. The biotech has a lead program licensed from MorphoSys in clinical development for two rare kidney diseases and $120 million to support that antibody and other biologic drugs in its pipeline.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.